Psychiatrie Ricany s.r.o.
- Address
- Bezrucova 296/22, 251 01 Ricany, Czechia
Psychiatrie Ricany s.r.o. - Schizophrenia Research Center
Psychiatrie Ricany s.r.o. is a specialized psychiatric research facility dedicated to advancing the treatment of serious mental health conditions. The center focuses on comprehensive evaluation of novel therapeutic interventions, with particular emphasis on long-term safety monitoring and cognitive function in psychiatric disorders.
- Long-term safety studies of investigational psychiatric medications
- Cognitive impairment associated with schizophrenia
- Phase III clinical trial programs for novel antipsychotic agents
The center participates in multi-phase clinical trial programs, including extended follow-up studies that monitor patients who have completed earlier treatment phases. Their expertise includes assessment of cognitive impairment due to schizophrenia and evaluation of Iclepertin, an investigational compound being studied through the CONNEX clinical trial program. By collecting additional safety data over extended treatment periods, Psychiatrie Ricany contributes valuable information about the long-term tolerability and effects of emerging psychiatric medications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Draig Therapeutics Limited1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Psychiatrie Ricany s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DT-101 in Adults with Major Depressive Disorder | Draig Therapeutics Limited | Phase II | Recruiting | Mar 2026 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Iclepertin | 1 | Unknown | 2022-03-29 | 2022-03-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.